COMMUNIQUÉS West-GlobeNewswire

Portés par ses activités pharmaceutiques, les résultats 2024 de Roquette démontrent la résilience de son modèle intégré
21/03/2025
Portés par ses activités pharmaceutiques, les résultats 2024 de Roquette démontrent la résilience de son modèle intégré Performances commerciales en ligne avec un marché qui reste en deçà des niveaux historiques. [...]
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
21/03/2025
Novartis receives third FDA approval for oral Fabhalta ® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Phase III study showed sustained proteinuria reduction at one year with favorable [...]
Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities
20/03/2025
ZUG, Switzerland, March 20, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to trades entered into by a PDMR of the Company pursuant to a 10b5-1 trading plan, in accordance with Rule 10b5-1(c)(1) of the [...]
vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
20/03/2025
Clinical hold lifted for late stage cadisegliatin program for diabetes CATT1 Phase 3 trial in patients with type 1 diabetes (T1D) expected to resume Q2 2025 Strengthens commercial leadership with appointment of Martin [...]
GENFIT Announces Completion of Non-dilutive Royalty Financing Agreement with HCRx and Results of Repurchase Offer to 2025 OCEANEs holders
20/03/2025
GENFIT completes a royalty financing of up to €185 million with HCRx after unanimous OCEANE bondholder approval, triggering a €130 million upfront payment with potential for an additional €55 million upon achieving near [...]
GENFIT annonce le closing du royalty financing avec HCRx et les résultats de l’Offre de Rachat aux porteurs d’OCEANEs 2025
20/03/2025
GENFIT a finalisé la mise en œuvre d’un royalty financing avec HCRx d’un montant maximum de 185 millions d'euros à la suite de l'approbation unanime des obligataires des OCEANEs 2025. Ce closing a déclenché un premier [...]
BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024
20/03/2025
Advancement of oral, brain-penetrant NLRP3 inhibitor BGE-102, with initial clinical data expected 2H25 Progression of preclinical next-generation APJ agonists for obesity New platform partnerships with Novartis and [...]
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer
20/03/2025
WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven [...]
BioRestorative Therapies to Report 2024 Financial Results and Host Conference Call on March 27, 2025
20/03/2025
MELVILLE, N.Y., March 20, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a clinical stage regenerative medicine innovator focused on stem cell- [...]
Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08
20/03/2025
GAITHERSBURG, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world, today [...]
Context Therapeutics Reports Full Year 2024 Operating and Financial Results
20/03/2025
CTIM-76 first patient dosed in January 2025 Cash and cash equivalents of $94.4 million as of December 31, 2024 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, March [...]
NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference
20/03/2025
Data evaluating safety and early signals of efficacy including updated local PFS from the completed dose escalation part of a Phase 1 study of re-irradiation with JNJ-1900 (NBTXR3) for patients with unresectable, [...]
NANOBIOTIX annonce la présentation de données issues de deux études de phase 1 évaluant JNJ-1900 (NBTXR3) lors du Congrès Européen sur le Cancer du Poumon
20/03/2025
Des données évaluant la sécurité et les premiers signes d’efficacité, y compris la mise à jour de la survie sans progression (SSP) locale, issues de la partie escalade de dose achevée d’une étude de Phase 1 sur la ré- [...]
Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer
20/03/2025
- Proven financial leader brings decades of experience in capital allocation, business development and shareholder value creation - WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: [...]
Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights
20/03/2025
– Four development candidates in clinical studies with data anticipated this year, continuing rapid progress of antiviral pipeline – – Interim Phase 1b proof-of-concept data, including initial efficacy measures, [...]
TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results
20/03/2025
MALVERN, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial [...]
Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
20/03/2025
VCAR33 clinical data update planned for first half of 2025 and trem-cel + Mylotarg clinical data update planned for second half of 2025 Anticipate initiation of the first trem-cel+VCAR33 Treatment System clinical trial [...]
Synergy CHC Corp. Announces Fourth Quarter and Full Year 2024 Earnings and Conference Call Information
20/03/2025
WESTBROOK, Maine, March 20, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a provider of consumer health care and lifestyle products, announced today that it plans to release [...]
Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
20/03/2025
- Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer - - Announced a clinical trial [...]

Pages